[go: up one dir, main page]

MA32634B1 - Polytherapie destinee a traiter une infection par le vhc - Google Patents

Polytherapie destinee a traiter une infection par le vhc

Info

Publication number
MA32634B1
MA32634B1 MA33700A MA33700A MA32634B1 MA 32634 B1 MA32634 B1 MA 32634B1 MA 33700 A MA33700 A MA 33700A MA 33700 A MA33700 A MA 33700A MA 32634 B1 MA32634 B1 MA 32634B1
Authority
MA
Morocco
Prior art keywords
infection
vhc
artemisinin
treatment
compound
Prior art date
Application number
MA33700A
Other languages
Arabic (ar)
English (en)
Inventor
David Huang
Gerhard Gustav Steinmann
Jerry O Stern
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41571875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32634(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA32634B1 publication Critical patent/MA32634B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne des combinaisons thérapeutiques comprenant (a) le composé (1), ou un sel pharmaceutiquement acceptable de celui-ci, tel que ci-décrit, (b) un interféron alpha et (c) de la ribavirine. Le composé (1) est un inhibiteur sélectif et puissant de la sérine protéase ns3 du vhc. La présente invention concerne également des procédés d'utilisation desdites combinaisons thérapeutiques pour traiter une infection par le vhc ou soulager un ou plusieurs de ses symptômes chez un patient.
MA33700A 2008-09-17 2011-03-14 Polytherapie destinee a traiter une infection par le vhc MA32634B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9775308P 2008-09-17 2008-09-17
US10903308P 2008-10-28 2008-10-28
US17193509P 2009-04-23 2009-04-23
PCT/US2009/056771 WO2010033443A1 (fr) 2008-09-17 2009-09-14 Polythérapie destinée à traiter une infection par le vhc

Publications (1)

Publication Number Publication Date
MA32634B1 true MA32634B1 (fr) 2011-09-01

Family

ID=41571875

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33700A MA32634B1 (fr) 2008-09-17 2011-03-14 Polytherapie destinee a traiter une infection par le vhc

Country Status (24)

Country Link
US (1) US8399484B2 (fr)
EP (1) EP2337583A1 (fr)
JP (1) JP5539363B2 (fr)
KR (1) KR20110054003A (fr)
CN (1) CN102159245B (fr)
AR (1) AR073516A1 (fr)
AU (1) AU2009293493B2 (fr)
BR (1) BRPI0918653A2 (fr)
CA (1) CA2737376A1 (fr)
CL (1) CL2011000571A1 (fr)
CO (1) CO6351753A2 (fr)
EA (1) EA019965B1 (fr)
EC (1) ECSP11010877A (fr)
IL (1) IL210152A0 (fr)
MA (1) MA32634B1 (fr)
MX (1) MX2011002602A (fr)
MY (1) MY152824A (fr)
NZ (1) NZ591030A (fr)
PE (1) PE20110343A1 (fr)
TW (1) TWI454263B (fr)
UA (1) UA103496C2 (fr)
UY (1) UY32124A (fr)
WO (1) WO2010033443A1 (fr)
ZA (1) ZA201009151B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
AU2009293493B2 (en) 2008-09-17 2014-09-18 Boehringer Ingelheim International Gmbh Combination of HCV NS3 protease inhibitor with interferon and ribavirin
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
JP2013505952A (ja) * 2009-09-28 2013-02-21 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新しい大環状阻害剤
CA2779244A1 (fr) * 2009-10-30 2011-05-05 Boehringer Ingelheim International Gmbh Regimes posologiques pour une therapie en combinaison contre le vhc comprenant bi201335, l'interferon alpha et la ribavirine
CA2813093A1 (fr) * 2010-09-30 2012-04-05 Boehringer Ingelheim International Gmbh Therapie combinee pour le traitement d'une infection par le vhc
CA2822556A1 (fr) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Inhibiteurs macrocycliques de serine protease d'hepatite c
CN103380132B (zh) 2010-12-30 2016-08-31 益安药业 菲啶大环丙型肝炎丝氨酸蛋白酶抑制剂
CA2824376C (fr) * 2011-01-10 2016-02-23 Proteus Digital Health, Inc. Systeme, procede et article pour encourager un changement de comportement
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
AU2013201532B2 (en) 2011-10-21 2014-10-02 Abbvie Ireland Unlimited Company Methods for treating HCV
EA201490837A1 (ru) 2011-10-21 2014-11-28 Эббви Инк. Способы лечения hcv, включающие по меньшей мере два противовирусных агента прямого действия, рибавирин, но не интерферон
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
WO2013137869A1 (fr) * 2012-03-14 2013-09-19 Boehringer Ingelheim International Gmbh Polythérapie pour le traitement d'une infection par le hcv dans une population de patients co-infectés hcv-hiv
US20140242029A1 (en) * 2013-02-27 2014-08-28 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
WO2013147750A1 (fr) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Polythérapie orale pour le traitement d'une infection au vhc dans une sous-population de patients spécifiques
WO2013147749A1 (fr) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Polythérapie orale pour le traitement d'une infection au vhc dans des populations de sous-génotypes de patients spécifiques
JP2015512900A (ja) * 2012-03-28 2015-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 特別な患者の遺伝子亜型分集団のｈｃｖ感染症を治療するための併用療法
WO2014138374A1 (fr) 2013-03-08 2014-09-12 Boehringer Ingelheim International Gmbh Polythérapie par voie orale pour le traitement d'une infection par le vhc chez une sous-population spécifique de patients
EP3089757A1 (fr) 2014-01-03 2016-11-09 AbbVie Inc. Formes galéniques antivirales solides
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4247479A (en) * 1976-12-03 1981-01-27 Hoechst Aktiengesellschaft Process for the manufacture of aromatic amines from α, β-unsaturated cycloaliphatic ketoximes
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
DE69632062T2 (de) * 1995-11-02 2004-11-18 Schering Corp. Kontinuierliche, niedrigdosierte zytokine-infusionstherapie
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US6472373B1 (en) * 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
RS50144B (sr) * 1998-06-08 2009-03-25 F. Hoffmann-La Roche Ag., Primena peg-inf-alfa 2a i ribavirina za proizvodnju leka za lečenje hroničnog hepatitisa c
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6824768B2 (en) * 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US6849254B1 (en) * 1999-04-19 2005-02-01 Schering Corporation HCV combination therapy
DE60129445T2 (de) * 2000-08-09 2008-04-24 F. Hoffmann-La Roche Ag Quinolin-derivate als antientzündungsmittel
EP2335700A1 (fr) * 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs de la polymerase du virus hepatitis C avec une structure heterobicylic
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7119072B2 (en) * 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US20050075279A1 (en) * 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US7601709B2 (en) * 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
CN1771257A (zh) * 2003-04-10 2006-05-10 贝林格尔·英格海姆国际有限公司 通过钌络合物催化的易位反应制备大环化合物的方法
JP4231524B2 (ja) * 2003-04-10 2009-03-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 大環状化合物の製造方法
ATE422895T1 (de) * 2003-04-16 2009-03-15 Bristol Myers Squibb Co Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
EA009295B1 (ru) * 2003-05-21 2007-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Соединения в качестве ингибиторов вируса гепатита с
RU2371195C2 (ru) * 2003-08-13 2009-10-27 Говард Дж. Смит Энд Эссошиэйтс Пти Лтд Способ лечения вирусных инфекций
RS20060197A (sr) * 2003-09-22 2008-09-29 Boehringer Ingelheim International Gmbh., Makrociklični peptidi koji su aktivni protiv hepatitisa c virusa
AR045870A1 (es) * 2003-10-11 2005-11-16 Vertex Pharma Terapia de combinacion para la infeccion de virus de hepatitis c
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
US7410979B2 (en) * 2003-11-19 2008-08-12 Rigel Pharmaceuticals, Inc. Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections
CN103319464A (zh) * 2004-02-20 2013-09-25 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
BRPI0508867A (pt) * 2004-03-15 2007-09-04 Boehringer Ingelheim Int processo para a preparação de compostos macrocìclicos
BRPI0509467A (pt) 2004-03-30 2007-09-11 Intermune Inc compostos macrocìclicos como inibidores de replicação viral
EP1753775B1 (fr) 2004-05-25 2012-12-26 Boehringer Ingelheim International GmbH Processus de preparation d'inhibiteurs de protease hcv acyclique
DE102004033312A1 (de) * 2004-07-08 2006-01-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Kontinuierliches Metatheseverfahren mit Ruthenium-Katalysatoren
DE602005026294D1 (de) * 2004-07-14 2011-03-24 Novartis Ag Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)
WO2006033851A1 (fr) * 2004-09-17 2006-03-30 Boehringer Ingelheim International, Gmbh Réaction de métathèse cyclisante en milieu fluide supercritique
JP2008513454A (ja) * 2004-09-17 2008-05-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 大環状ｈｃｖプロテアーゼインヒビターの調製方法
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
US20070274951A1 (en) * 2006-02-09 2007-11-29 Xiao Tong Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto
WO2008070358A2 (fr) * 2006-11-16 2008-06-12 Phenomix Corporation Inhibiteurs de la sérine protéase de l'hépatite c et utilisations de ceux-ci
JP5465666B2 (ja) 2007-06-29 2014-04-09 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス化合物
KR20100038417A (ko) 2007-06-29 2010-04-14 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
WO2009014730A1 (fr) 2007-07-26 2009-01-29 Idenix Pharmaceuticals, Inc. Inhibiteurs macrocycliques de la sérine protéase
WO2009021121A2 (fr) 2007-08-08 2009-02-12 Wyeth Identification et caractérisation de variants de réplicon de vhc présentant une sensibilité réduite à une combinaison d'inhibiteurs de polymérase et de protéase, et procédés connexes
WO2009099596A2 (fr) 2008-02-04 2009-08-13 Idenix Pharamaceuticals, Inc. Inhibiteurs de sérine protéase macrocycliques
AU2009293494B2 (en) 2008-09-16 2014-04-24 Boehringer Ingelheim International Gmbh Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent HCV inhibitor
AU2009293493B2 (en) 2008-09-17 2014-09-18 Boehringer Ingelheim International Gmbh Combination of HCV NS3 protease inhibitor with interferon and ribavirin
AR073603A1 (es) 2008-09-18 2010-11-17 Ortho Mcneil Janssen Pharm Combinaciones sinergicas de un inhibidor macrociclico del vhc y un nucleosido
UA104195C2 (ru) * 2009-07-07 2014-01-10 Берингер Ингельхайм Интернациональ Гмбх Фармацевтическая композиция ингибитора протеазы вируса гепатита c
CA2779244A1 (fr) 2009-10-30 2011-05-05 Boehringer Ingelheim International Gmbh Regimes posologiques pour une therapie en combinaison contre le vhc comprenant bi201335, l'interferon alpha et la ribavirine
US8530497B2 (en) 2010-03-11 2013-09-10 Boehringer Ingelheim International Gmbh Crystalline salts of a potent HCV inhibitor
CA2813093A1 (fr) * 2010-09-30 2012-04-05 Boehringer Ingelheim International Gmbh Therapie combinee pour le traitement d'une infection par le vhc

Also Published As

Publication number Publication date
JP2012502999A (ja) 2012-02-02
US20100068182A1 (en) 2010-03-18
UY32124A (es) 2010-04-30
EA019965B1 (ru) 2014-07-30
PE20110343A1 (es) 2011-06-25
ECSP11010877A (es) 2011-04-29
BRPI0918653A2 (pt) 2015-12-01
TW201016218A (en) 2010-05-01
AU2009293493B2 (en) 2014-09-18
CA2737376A1 (fr) 2010-03-25
HK1156865A1 (en) 2012-06-22
EP2337583A1 (fr) 2011-06-29
JP5539363B2 (ja) 2014-07-02
US8399484B2 (en) 2013-03-19
CO6351753A2 (es) 2011-12-20
NZ591030A (en) 2012-10-26
AR073516A1 (es) 2010-11-10
WO2010033443A1 (fr) 2010-03-25
AU2009293493A1 (en) 2010-03-25
CN102159245B (zh) 2013-07-24
UA103496C2 (uk) 2013-10-25
EA201100506A1 (ru) 2011-10-31
TWI454263B (zh) 2014-10-01
MY152824A (en) 2014-11-28
IL210152A0 (en) 2011-03-31
ZA201009151B (en) 2011-09-28
MX2011002602A (es) 2011-04-07
KR20110054003A (ko) 2011-05-24
CN102159245A (zh) 2011-08-17
CL2011000571A1 (es) 2011-07-29

Similar Documents

Publication Publication Date Title
MA32634B1 (fr) Polytherapie destinee a traiter une infection par le vhc
EA200970805A1 (ru) Ингибиторы серинпротеаз для лечения hcv инфекций
EA200900969A1 (ru) Макроциклические ингибиторы протеазы гепатита с
EA200901101A1 (ru) Макроциклические соединения в качестве ингибиторов протеазы ns3 вгс
EA200900298A1 (ru) Ингибиторы вируса гепатита с
EA200901241A1 (ru) Соединения для лечения гепатита с
CY1114356T1 (el) Αναστολεις του ιου της ηπατιτιδας c
EA201200890A1 (ru) Комбинированная терапия hcv
WO2008106058A3 (fr) Inhibiteurs de sérine protéases
WO2007089618A3 (fr) Inhibiteurs de la sérine protéase de l'hépatite c et leurs utilisations
ATE547103T1 (de) Hemmer des hepatitis-c-virus
ATE512976T1 (de) Hemmer des hepatitis-c-virus
EA200800371A1 (ru) Ингибиторы ns3 протеазы вгс
CY1111212T1 (el) Θειικες ενωσεις ως αναστολεις της πρωτεασης σερινης ns3 του ιου της ηπατιτιδας γ
WO2009055335A3 (fr) Inhibiteurs des protéases du vhc
WO2006130627A3 (fr) Methodes de traitement de l'hepatite c
EA200700243A1 (ru) Способы лечения гепатита с
EA200802346A1 (ru) Циклопропилконденсированные индолобензазепиновые ингибиторы белка ns5b вируса гепатита с
EA200500584A1 (ru) Нуклеозидные производные для лечения инфекционных заболеваний, вызванных вирусом гепатита c
NO20075655L (no) Terapeutisk RNAI for respiratorisk virusinfeksjon
MY141003A (en) Materials and methods for treating viral infections with a cysteamine compound
WO2008036899A3 (fr) Procédés d'élimination des contaminants viraux durant la purification des protéines
EA201000277A1 (ru) Соединения для лечения гепатита с
MX2010004704A (es) Inhibidores macrociclicos de la ns3 serina proteasa del virus de la hepatitis c.
EA201200650A1 (ru) Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин